Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals

Yuchuan Zhuang, Xing Qiu, Lu Wang, Qing Ma, Mark Mapstone, Amneris Luque, Miriam Weber, Madalina Tivarus, Eric Miller, Roberto C. Arduino, Jianhui Zhong, Giovanni Schifitto

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Our study aimed to investigate the short-term effect of combination antiretroviral therapy (cART) on cognitive performance and functional and structural connectivity and their relationship to plasma levels of antiretroviral (ARV) drugs. Seventeen ARV treatment-naïve HIV-infected individuals (baseline mean CD4 cell count, 479 ± 48 cells/mm3) were age matched with 17 HIV-uninfected individuals. All subjects underwent a detailed neurocognitive and functional assessment and magnetic resonance imaging. HIV-infected subjects were scanned before starting cART and 12 weeks after initiation of treatment. Uninfected subjects were assessed once at baseline. Functional connectivity (FC) was assessed within the default mode network while structural connectivity was assessed by voxel-wise analysis using tract-based spatial statistics (TBSS) and probabilistic tractography within the DMN. Tenofovir and emtricitabine blood concentration were measured at week 12 of cART. Prior to cART, HIV-infected individuals had significantly lower cognitive performance than control subjects as measured by the total Z-score from the neuropsychological tests assessing six cognitive domains (p = 0.020). After 12 weeks of cART treatment, there remained only a weak cognitive difference between HIV-infected and HIV-uninfected subjects (p = 0.057). Mean FC was lower in HIV-infected individuals compared with those uninfected (p = 0.008), but FC differences became non-significant after treatment (p = 0.197). There were no differences in DTI metrics between HIV-infected and HIV-uninfected individuals using the TBSS approach and limited evidence of decreased structural connectivity within the DMN in HIV-infected individuals. Tenofovir and emtricitabine plasma concentrations did not correlate with either cognitive performance or imaging metrics. Conclusions: Twelve weeks of cART improves cognitive performance and functional connectivity in ARV treatment-naïve HIV-infected individuals with relatively preserved immune function. Longer periods of observation are necessary to assess whether this effect is maintained.

Original languageEnglish (US)
Pages (from-to)704-712
Number of pages9
JournalJournal of NeuroVirology
Volume23
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Cognitive Therapy
HIV
Tenofovir
Neuropsychological Tests
Therapeutics
CD4 Lymphocyte Count
Magnetic Resonance Imaging
Observation

Keywords

  • Cognitive function
  • Combination antiretroviral therapy
  • Diffusion tensor imaging
  • Functional magnetic resonance imaging
  • HIV infection

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Cite this

Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals. / Zhuang, Yuchuan; Qiu, Xing; Wang, Lu; Ma, Qing; Mapstone, Mark; Luque, Amneris; Weber, Miriam; Tivarus, Madalina; Miller, Eric; Arduino, Roberto C.; Zhong, Jianhui; Schifitto, Giovanni.

In: Journal of NeuroVirology, Vol. 23, No. 5, 01.10.2017, p. 704-712.

Research output: Contribution to journalArticle

Zhuang, Y, Qiu, X, Wang, L, Ma, Q, Mapstone, M, Luque, A, Weber, M, Tivarus, M, Miller, E, Arduino, RC, Zhong, J & Schifitto, G 2017, 'Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals', Journal of NeuroVirology, vol. 23, no. 5, pp. 704-712. https://doi.org/10.1007/s13365-017-0553-9
Zhuang, Yuchuan ; Qiu, Xing ; Wang, Lu ; Ma, Qing ; Mapstone, Mark ; Luque, Amneris ; Weber, Miriam ; Tivarus, Madalina ; Miller, Eric ; Arduino, Roberto C. ; Zhong, Jianhui ; Schifitto, Giovanni. / Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals. In: Journal of NeuroVirology. 2017 ; Vol. 23, No. 5. pp. 704-712.
@article{6a463671279f4a37bafab7a0f3355bab,
title = "Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-na{\"i}ve HIV-infected individuals",
abstract = "Our study aimed to investigate the short-term effect of combination antiretroviral therapy (cART) on cognitive performance and functional and structural connectivity and their relationship to plasma levels of antiretroviral (ARV) drugs. Seventeen ARV treatment-na{\"i}ve HIV-infected individuals (baseline mean CD4 cell count, 479 ± 48 cells/mm3) were age matched with 17 HIV-uninfected individuals. All subjects underwent a detailed neurocognitive and functional assessment and magnetic resonance imaging. HIV-infected subjects were scanned before starting cART and 12 weeks after initiation of treatment. Uninfected subjects were assessed once at baseline. Functional connectivity (FC) was assessed within the default mode network while structural connectivity was assessed by voxel-wise analysis using tract-based spatial statistics (TBSS) and probabilistic tractography within the DMN. Tenofovir and emtricitabine blood concentration were measured at week 12 of cART. Prior to cART, HIV-infected individuals had significantly lower cognitive performance than control subjects as measured by the total Z-score from the neuropsychological tests assessing six cognitive domains (p = 0.020). After 12 weeks of cART treatment, there remained only a weak cognitive difference between HIV-infected and HIV-uninfected subjects (p = 0.057). Mean FC was lower in HIV-infected individuals compared with those uninfected (p = 0.008), but FC differences became non-significant after treatment (p = 0.197). There were no differences in DTI metrics between HIV-infected and HIV-uninfected individuals using the TBSS approach and limited evidence of decreased structural connectivity within the DMN in HIV-infected individuals. Tenofovir and emtricitabine plasma concentrations did not correlate with either cognitive performance or imaging metrics. Conclusions: Twelve weeks of cART improves cognitive performance and functional connectivity in ARV treatment-na{\"i}ve HIV-infected individuals with relatively preserved immune function. Longer periods of observation are necessary to assess whether this effect is maintained.",
keywords = "Cognitive function, Combination antiretroviral therapy, Diffusion tensor imaging, Functional magnetic resonance imaging, HIV infection",
author = "Yuchuan Zhuang and Xing Qiu and Lu Wang and Qing Ma and Mark Mapstone and Amneris Luque and Miriam Weber and Madalina Tivarus and Eric Miller and Arduino, {Roberto C.} and Jianhui Zhong and Giovanni Schifitto",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s13365-017-0553-9",
language = "English (US)",
volume = "23",
pages = "704--712",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals

AU - Zhuang, Yuchuan

AU - Qiu, Xing

AU - Wang, Lu

AU - Ma, Qing

AU - Mapstone, Mark

AU - Luque, Amneris

AU - Weber, Miriam

AU - Tivarus, Madalina

AU - Miller, Eric

AU - Arduino, Roberto C.

AU - Zhong, Jianhui

AU - Schifitto, Giovanni

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Our study aimed to investigate the short-term effect of combination antiretroviral therapy (cART) on cognitive performance and functional and structural connectivity and their relationship to plasma levels of antiretroviral (ARV) drugs. Seventeen ARV treatment-naïve HIV-infected individuals (baseline mean CD4 cell count, 479 ± 48 cells/mm3) were age matched with 17 HIV-uninfected individuals. All subjects underwent a detailed neurocognitive and functional assessment and magnetic resonance imaging. HIV-infected subjects were scanned before starting cART and 12 weeks after initiation of treatment. Uninfected subjects were assessed once at baseline. Functional connectivity (FC) was assessed within the default mode network while structural connectivity was assessed by voxel-wise analysis using tract-based spatial statistics (TBSS) and probabilistic tractography within the DMN. Tenofovir and emtricitabine blood concentration were measured at week 12 of cART. Prior to cART, HIV-infected individuals had significantly lower cognitive performance than control subjects as measured by the total Z-score from the neuropsychological tests assessing six cognitive domains (p = 0.020). After 12 weeks of cART treatment, there remained only a weak cognitive difference between HIV-infected and HIV-uninfected subjects (p = 0.057). Mean FC was lower in HIV-infected individuals compared with those uninfected (p = 0.008), but FC differences became non-significant after treatment (p = 0.197). There were no differences in DTI metrics between HIV-infected and HIV-uninfected individuals using the TBSS approach and limited evidence of decreased structural connectivity within the DMN in HIV-infected individuals. Tenofovir and emtricitabine plasma concentrations did not correlate with either cognitive performance or imaging metrics. Conclusions: Twelve weeks of cART improves cognitive performance and functional connectivity in ARV treatment-naïve HIV-infected individuals with relatively preserved immune function. Longer periods of observation are necessary to assess whether this effect is maintained.

AB - Our study aimed to investigate the short-term effect of combination antiretroviral therapy (cART) on cognitive performance and functional and structural connectivity and their relationship to plasma levels of antiretroviral (ARV) drugs. Seventeen ARV treatment-naïve HIV-infected individuals (baseline mean CD4 cell count, 479 ± 48 cells/mm3) were age matched with 17 HIV-uninfected individuals. All subjects underwent a detailed neurocognitive and functional assessment and magnetic resonance imaging. HIV-infected subjects were scanned before starting cART and 12 weeks after initiation of treatment. Uninfected subjects were assessed once at baseline. Functional connectivity (FC) was assessed within the default mode network while structural connectivity was assessed by voxel-wise analysis using tract-based spatial statistics (TBSS) and probabilistic tractography within the DMN. Tenofovir and emtricitabine blood concentration were measured at week 12 of cART. Prior to cART, HIV-infected individuals had significantly lower cognitive performance than control subjects as measured by the total Z-score from the neuropsychological tests assessing six cognitive domains (p = 0.020). After 12 weeks of cART treatment, there remained only a weak cognitive difference between HIV-infected and HIV-uninfected subjects (p = 0.057). Mean FC was lower in HIV-infected individuals compared with those uninfected (p = 0.008), but FC differences became non-significant after treatment (p = 0.197). There were no differences in DTI metrics between HIV-infected and HIV-uninfected individuals using the TBSS approach and limited evidence of decreased structural connectivity within the DMN in HIV-infected individuals. Tenofovir and emtricitabine plasma concentrations did not correlate with either cognitive performance or imaging metrics. Conclusions: Twelve weeks of cART improves cognitive performance and functional connectivity in ARV treatment-naïve HIV-infected individuals with relatively preserved immune function. Longer periods of observation are necessary to assess whether this effect is maintained.

KW - Cognitive function

KW - Combination antiretroviral therapy

KW - Diffusion tensor imaging

KW - Functional magnetic resonance imaging

KW - HIV infection

UR - http://www.scopus.com/inward/record.url?scp=85027062056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027062056&partnerID=8YFLogxK

U2 - 10.1007/s13365-017-0553-9

DO - 10.1007/s13365-017-0553-9

M3 - Article

C2 - 28791662

AN - SCOPUS:85027062056

VL - 23

SP - 704

EP - 712

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 5

ER -